Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00903266 · ClinicalTrials.gov registry record · Phase 3

Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia

A Phase 3 study, sponsored by Beth Israel Deaconess Medical Center.

Completed
Registry status
Phase 3
Development phase
30
Enrollment target

NCT00903266: Completed Phase 3 study, sponsored by Beth Israel Deaconess Medical Center.

NCT00903266 is a Phase 3 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 30 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00903266, a Phase 3 study, has completed, sponsored by Beth Israel Deaconess Medical Center.

COMPLETED
Registry status
Phase 3
Development phase
30 participants
Enrollment target

Study Summary

We are doing this clinical trial in order to evaluate two different treatments for non-fluent aphasia: Melodic Intonation Therapy (MIT) and Speech Repetition Therapy (SRT). MIT uses a simple form of singing, while SRT uses intensive repetition of a set of words and phrases. We want to see which intensive form of treatment is more effective in leading to an improvement in speech output compared to a no-therapy control period, and whether either treatment can cause changes in brain activity during speaking and changes in brain structure. We will use a technique known as functional Magnetic Resonance Imaging (fMRI) to measure blood flow changes in the brain and structural MRI that assess brain anatomy and connections between brain regions. We will use fMRI to assess brain activity while a patient speaks, sings, and hums. We will assess changes in brain activity and in brain structure by comparing scans done prior to treatment to scans obtained after treatment and we will also examine changes between treatment groups. We will correlate changes in brain activity and brain structure with changes in language test scores.

Interventions

  • BEHAVIORAL Melodic Intonation Therapy
  • BEHAVIORAL Speech-Repetition-Therapy

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-02
Est. Completion 2020-06
Phase Phase 3

What the finished NCT00903266 record still lists

NCT00903266 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Melodic Intonation Therapy is the first listed.

NCT00903266 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00903266 about?

NCT00903266 is a clinical study titled "Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia". We are doing this clinical trial in order to evaluate two different treatments for non-fluent aphasia: Melodic Intonation Therapy (MIT) and Speech Repetition Therapy (SRT). MIT uses a simple form of singing, while SRT uses intensive repetition of a set of words and phrases. We want to see which inte...

What is the current status of trial NCT00903266?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2008-02. Estimated completion is 2020-06.

What interventions are being tested in trial NCT00903266?

The interventions under investigation include: Melodic Intonation Therapy (BEHAVIORAL), Speech-Repetition-Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT00903266?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00903266's enrollment target sits among peer trials

30 1917th of 2000 higher than 68 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00903266, the US trial registry maintained by the National Library of Medicine. NCT00903266 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.